Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $933,553.87 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 52,183 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total transaction of $933,553.87. Following the transaction, the chief financial officer now directly owns 225,571 shares in the company, valued at $4,035,465.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Day One Biopharmaceuticals Stock Down 2.3 %

Shares of Day One Biopharmaceuticals stock opened at $17.17 on Monday. Day One Biopharmaceuticals, Inc. has a 52-week low of $9.67 and a 52-week high of $18.07. The firm’s 50 day moving average price is $15.45 and its 200-day moving average price is $14.07. The company has a market cap of $1.50 billion, a P/E ratio of -7.21 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.67 EPS for the current fiscal year.

Analyst Ratings Changes

DAWN has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. JPMorgan Chase & Co. raised their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DAWN. Vanguard Group Inc. raised its stake in Day One Biopharmaceuticals by 8.1% in the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after buying an additional 346,090 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Day One Biopharmaceuticals by 38.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock worth $5,486,000 after purchasing an additional 125,050 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Day One Biopharmaceuticals by 22.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after purchasing an additional 40,387 shares in the last quarter. TimesSquare Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 41.8% in the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock worth $14,020,000 after buying an additional 336,910 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Day One Biopharmaceuticals by 5.5% during the third quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock worth $2,173,000 after buying an additional 9,219 shares during the period. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.